Inactive Instrument

Cyteir Therapeutics, Inc.

CYTT

US23284P1030

Biotechnology & Medical Research

Cyteir Therapeutics, Inc.(OTCPK:CYTT) dropped from NASDAQ Composite Index

March 14, 2024

Cyteir Therapeutics, Inc. removed

Latest news about Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc. Estimates Common Stock Liquidation Distributions	Mar. 20	CI
Cyteir Therapeutics, Inc.(NasdaqGS:CYT) dropped from S&P TMI Index	Mar. 19	CI
Cyteir Therapeutics, Inc.(OTCPK:CYTT) dropped from NASDAQ Composite Index	Mar. 14	CI
Cyteir Therapeutics, Inc. Announces Resignation of Timothy Romberger from Board of Directors	Dec. 07	CI
Cyteir Therapeutics, Inc. Announces Board Changes	Dec. 05	CI
Cyteir Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Cyteir Therapeutics' Ovarian Cancer Combination Treatment Candidate Shows 91% Overall Disease Control in Phase 1 Study	23-10-12	MT
Cyteir Therapeutics, Inc. Presents Ongoing Results from a Dose Expansion Cohort of CYT-0851 in Combination with Capecitabine in Advanced Platinum-Resistant Ovarian Cancer	23-10-12	CI
Cyteir Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Top Midday Gainers	23-06-30	MT
Cyteir Therapeutics, Inc. Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution	23-06-30	CI
Cyteir Therapeutics to Discontinue CYT-0851 Development, Plans Dissolution, Liquidation of Assets; Shares Rise Pre-Bell	23-06-30	MT
Cyteir Therapeutics' Board Recommends Liquidation, Dissolution of Assets	23-06-30	MT
Cyteir Therapeutics, Inc. Presents Results from A Phase 1 Study with CYT-0851	23-06-03	CI
Cyteir Therapeutics, Inc. Announces Resignation of Adam Veness from His Position as General Counsel and Secretary, to Be Effective as of the Company’S Annual Meeting of Stockholders on June 14, 2023	23-06-02	CI
Cyteir Therapeutics, Inc. Announces Resignation of Susan Molineaux from the Board of Directors	23-05-31	CI
Athira Pharma Names Andrew Gengos CFO	23-05-22	MT
Cyteir Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Cyteir Therapeutics Appoints David Gaiero Finance Chief	23-02-06	MT
Cyteir Therapeutics, Inc. Announces the Promotion of David Gaiero to Chief Financial Officer	23-02-06	CI
Morgan Stanley Downgrades Cyteir Therapeutics to Underweight From Equal Weight, Adjusts Price Target to $2 From $4	23-02-03	MT
BofA Securities Downgrades Cyteir Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $4	23-01-30	MT
Wedbush Lowers Cyteir Therapeutics' Price Target to $3 From $8, Notes 'Disappointing' Monotherapy Results; Keeps Outperform Rating	23-01-23	MT
JPMorgan Downgrades Cyteir Therapeutics to Neutral From Overweight	23-01-20	MT
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development	23-01-19	CI

Chart Cyteir Therapeutics, Inc.

Duration

Period

More charts

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. Its CYT-0851 is also in development in combination with capecitabine and gemcitabine in a Phase I/II clinical study, including patients with advanced ovarian cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+47.98%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research